With all above associations and with first findings of the relationship between the different allelic distribution of selected NKG2D ligands in AML patients compared to healthy donors, we believe that individual polymorphisms could have a broader impact on AML development and progression. The gene discussed is KLRK1; the disease is acute myeloid leukemia.